Vedana Therapeutics

Vedana Therapeutics is a clinical-stage biotechnology company developing next-generation medicines for migraine prevention. Founded by biotech investor Anurag Agarwal and antibody-development veteran Leon Garcia, the company emerged from stealth in June 2026 with a $46 million Series A co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana is building a portfolio of long-acting, subcutaneously dosed monoclonal antibodies that go beyond CGRP by targeting PACAP (pituitary adenylate cyclase-activating peptide) and other CGRP-independent pathways, aiming to deliver complete and lasting relief for the majority of migraine patients who remain suboptimally controlled on current standard of care. Its preclinical pipeline includes VDN-0100 (anti-PACAP antibody, first-in-human planned 2027), VDN-0200 (PACAP x CGRP bispecific), and two undisclosed programs. This profile was surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network. Vedana is a therapeutics company and publishes no public API or developer surface; this record captures its corporate identity for discovery.

Vedana Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Pharmaceuticals, and Neuroscience.

Vedana Therapeutics’ developer surface includes engineering blog, support, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyTherapeuticsPharmaceuticalsNeuroscienceMigraineAntibodiesDrug DiscoveryLife SciencesHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.9/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/vedana-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 3

The organization behind the API

Website

Website

About

About

Blog

Blog

Other 2

Properties that don't map to a standard resource type

Team

Team

Accessibility

Accessibility

Source (apis.yml)

aid: vedana-therapeutics
name: Vedana Therapeutics
description: Vedana Therapeutics is a clinical-stage biotechnology company developing next-generation medicines for migraine
  prevention. Founded by biotech investor Anurag Agarwal and antibody-development veteran Leon Garcia, the company emerged
  from stealth in June 2026 with a $46 million Series A co-led by Westlake BioPartners and Canaan Partners, with participation
  from Dawn Biopharma and Alexandria Venture Investments. Vedana is building a portfolio of long-acting, subcutaneously dosed
  monoclonal antibodies that go beyond CGRP by targeting PACAP (pituitary adenylate cyclase-activating peptide) and other
  CGRP-independent pathways, aiming to deliver complete and lasting relief for the majority of migraine patients who remain
  suboptimally controlled on current standard of care. Its preclinical pipeline includes VDN-0100 (anti-PACAP antibody, first-in-human
  planned 2027), VDN-0200 (PACAP x CGRP bispecific), and two undisclosed programs. This profile was surfaced as a portfolio
  company of Canaan Partners and added to the API Evangelist network. Vedana is a therapeutics company and publishes no public
  API or developer surface; this record captures its corporate identity for discovery.
url: https://raw.githubusercontent.com/api-evangelist/vedana-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
- westlake-biopartners
x-tier: stub
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
image: https://vedanatx.com/wp-content/themes/vedana-thera/images/favicon/apple-touch-icon.png
tags:
- Company
- Biotechnology
- Therapeutics
- Pharmaceuticals
- Neuroscience
- Migraine
- Antibodies
- Drug Discovery
- Life Sciences
- Healthcare
apis: []
common:
- type: Website
  url: https://vedanatx.com/
- type: About
  url: https://vedanatx.com/science/
- type: Team
  url: https://vedanatx.com/leadership/
- type: Blog
  url: https://vedanatx.com/news/
- type: Support
  url: https://vedanatx.com/contact/
- type: PrivacyPolicy
  url: https://vedanatx.com/privacy-statement/
- type: Accessibility
  url: https://vedanatx.com/accessibility-statement/
- type: LLMsTxt
  url: llms/vedana-therapeutics-llms.txt
- type: DomainSecurity
  url: security/vedana-therapeutics-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: enriched
  artifacts_added: 2
  pass: local-v1